Avidity Biosciences (RNA) FCF Margin (2019 - 2025)
Historic FCF Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1257.6%.
- Avidity Biosciences' FCF Margin rose 16242100.0% to 1257.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 2838.14%, marking a year-over-year decrease of 9748300.0%. This contributed to the annual value of 2825.88% for FY2024, which is 15362100.0% down from last year.
- Latest data reveals that Avidity Biosciences reported FCF Margin of 1257.6% as of Q3 2025, which was up 16242100.0% from 5277.07% recorded in Q2 2025.
- Avidity Biosciences' FCF Margin's 5-year high stood at 713.09% during Q4 2023, with a 5-year trough of 8174.32% in Q1 2025.
- Moreover, its 5-year median value for FCF Margin was 1689.81% (2022), whereas its average is 2202.46%.
- In the last 5 years, Avidity Biosciences' FCF Margin skyrocketed by 21590600bps in 2023 and then crashed by -61620400bps in 2025.
- Avidity Biosciences' FCF Margin (Quarter) stood at 1507.67% in 2021, then increased by 4bps to 1445.97% in 2022, then surged by 149bps to 713.09% in 2023, then plummeted by -590bps to 3490.99% in 2024, then soared by 64bps to 1257.6% in 2025.
- Its last three reported values are 1257.6% in Q3 2025, 5277.07% for Q2 2025, and 8174.32% during Q1 2025.